| Document |
Document Title |
|
WO/2007/028814A1 |
The invention relates to a crystalline hydrate of 1-chloro-4-(ß-D-glucopyranos-1-yl)-2-(4- ethynyl-benzyl)-benzene and to crystalline complexes between 1-chloro-4-(ß-D- 5 glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and a natural am...
|
|
WO/2007/025943A2 |
Glucopyranosyl-substituted benzyl-benzene derivatives of the general formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereo...
|
|
WO/2007/013609A1 |
Fucoidan is a sulfated polysaccharide having an extremely large molecular weight. In the development of pharmaceuticals and health foods using fucoidan, there are problems with respect to absorption property, antigenicity, homogeneity, a...
|
|
WO/2006/120576A2 |
An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit ...
|
|
WO/2006/108842A1 |
Glucopyranosyloxy-substituted (heteroaryloxy-benzyl)-benzene derivatives of the general formula (I), where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof,...
|
|
WO/2006/105440A2 |
Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders incl...
|
|
WO/2006/083780A2 |
This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolo...
|
|
WO/2006/064033A2 |
Glucopyranosyl-substituted benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the tr...
|
|
WO/2006/059670A1 |
It is intended to provide a sialic acid-containing complex capable of capturing viruses of a large number of types and a virus-capturing agent originating in a natural material with the use of the same. Namely, a chitosan complex wherein...
|
|
WO/2006/037537A2 |
Disclosed are D-pyranosyl-substituted phenyls of general formula (I), wherein the radicals R1 to R5, X, Z, and R7a, R7b, R7c are defined as indicated in claim 1. Said phenyls have an inhibitory effect on the sodium-dependent glucose cotr...
|
|
WO/2006/034489A2 |
A compound of the formula (I) A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.
|
|
WO/2006/008038A1 |
D-xylopyranosyl-substituted phenyls of general formula (I), in which radicals R1 to R5, X, Z as well as R7a, R7b and R7c are defined as in Claim 1, exhibit an inhibiting effect upon the sodium-dependent glucose-cotransporter SGLT. The in...
|
|
WO/2006/006496A1 |
A process for producing azulene derivatives useful as Na+-glucose cotransporter inhibitor easily and simply in high yield at a low cost which is industrially advantageous and excellent in environmental protection, characterized by subjec...
|
|
WO/2006/002912A1 |
The invention relates to D-xylopyranosyl-substituted phenyls of general formula (I) wherein the radicals R1 to R5, X, Z and R7a, R7b, R7c have the designations cited in patent claim 1, said phenyls having an inhibiting effect on the sodi...
|
|
WO/2005/063797A1 |
The present invention provides novel nonnatural C-linked carbo-β-peptides with robust secondary structures, which comprises the synthesis of a new class of β-peptides called C-linked carbo-β-peptides, most of which are favorably dispo...
|
|
WO/2005/058972A1 |
The present invention relates to a process for the oxidation of a hydroxy compound comprising the steps of: a) providing a first mixture containing an organic protonated hydroxylamine compound, b) oxidizing said protonated hydroxylamine ...
|
|
WO/2005/056511A1 |
The invention relates to a method for the production of 2-keto-L-gulonic acid-C1-C10-alkyl esters by esterification of 2-keto-L-gulonic acid hydrate with an anhydrous C1-C10-alkyl alcohol in the presence of an acid homogeneous catalyst i...
|
|
WO/2005/012318A2 |
This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
|
|
WO/2004/113358A1 |
This invention relates to a process for preparing 2'-deoxynucleoside compounds or 2'-deoxynucleoside precursors using 2-dehydro-3-deoxy-D-gluconic acid (usually abbreviated as KDG) or its salts as a starting material. A variety of 2'-deo...
|
|
WO/2004/105753A1 |
An antidepressant or a food or beverage for antidepression. The antidepressant and the food or beverage contain as an active ingredient either a compound represented by the formula (I): (I) (wherein R1, R2, R3, and R4 are the same or dif...
|
|
WO/2004/094444A1 |
This invention relates to galactosylceramide compounds.
|
|
WO/2004/094445A1 |
A novel C-glycoside of isopropylthiogalactoside (IPTG), isobutyl-C-galactoside (IBCG), is described. IBCG may be used as an IPTG substitute for increased induction of protein expression of plasmid-based genes for the production of recomb...
|
|
WO/2004/089277A2 |
Fused oxabicyclic aminoalcohols of formula (I) and (II) processes for their preparation and uses thereof as scaffolds for preparing libraries of compounds of formula (XXVII) and (XXVIII) wherein the meanings of RI, R2,R3,R4 and R5 are re...
|
|
WO/2004/084912A1 |
It is intended to provide a remedy for nerve damage caused by spinal injury, nerve trauma or the like which contains, as the active ingredient, a low-molecular weight saccharide at least having glucuronic acid and/or N-acetylglucosamine ...
|
|
WO/2004/075843A2 |
It is taught here that enkephalin peptides which are glycosylated with a disaccharide will be transported across the blood brain barrier and deliver analgesic effects superior to morphine when introduced into the bloodstream. Glycosylate...
|
|
WO/2004/076470A2 |
The present invention provides a method for making glycoside compounds including the steps of: (a) lithiating an aromatic reactant having a leaving group using lithium reagent in a first microreactor under non-cryogenic conditions to for...
|
|
WO/2004/063209A2 |
Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.
|
|
WO/2004/056841A1 |
The invention relates to a method for extracting 2-ketone-L-gulonic acids from a polar, preferably aqueous solvent, preferably from a solvent which contains a mixture of ascorbic acid and 2-ketone-L-gulonic acid, by means of liquid-liqui...
|
|
WO/2004/052899A2 |
The present invention provides an improved process for preparing ß-D and ß-L 2'-C-methyl-nucleosides and 2'-C-methyl-3'-O-ester nucleosides.
|
|
WO/2004/043880A2 |
The invention relates to a method for producing 2-keto-L-gulonic acid-C4-C10 alkyl ester by esterifying 2-keto-L-gulonic acid (KGS) with an unsaturated, branched or unbranched C4-C10 alcohol. The inventive method is characterized by the ...
|
|
WO/2004/039373A1 |
Bis- and trisazasugar derivatives and processes for the preparation thereof are disclosed herein. The disclosed compounds have &agr -glucosidase inhibiting properties, and are useful in the treatment of diabetes. Pharmaceutical compositi...
|
|
WO/2004/033472A1 |
The invention relates to a method for producing monomer uronic acids, especially mannuronic acid and guluronic acid, preferably from microbially produced polymannuronate or polyguluronate, and to the pharmacologically active derivatives ...
|
|
WO/2004/007713A1 |
It is intended to provide a nucleoside or a nucleotide having a novel unnatural base. Namely, a nucleoside or a nucleotide having a 5-substituted-2-oxo(1H)-pyridin-3-yl group as a base. It is preferable that the base is substituted at th...
|
|
WO/2004/007517A1 |
The invention relates to novel thiophenylglycoside derivatives of formula (I), where the groups have the given meanings, the physiologically-acceptable salts and methods for production thereof. The compounds are suitable as anti-diabetic...
|
|
WO/2004/005311A1 |
The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof. Processes for the isolating of this bafilomycin metabolite from a novel Micromonospora species, pharmaceutical compositions containing this m...
|
|
WO2002078747A9 |
In accordance with the present invention, there is provided pregabalin lactose conjugate compounds. Also provided as part of the present invention is a novel method of central nervous system disorders or diseases including seizure disord...
|
|
WO/2003/105769A2 |
The invention is directed to compounds of formula (I) wherein X is O, OR NH; R’ is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q’ is optionally present and may be a C1-10 h...
|
|
WO/2003/104248A2 |
Disclosed are derivatives of general formula (I), in which x equals zero or one, R1 represents -(CH2)n-CH3, n ranging between 3 and 21, R2 and R3, which can be identical or different, represent one or another of the following substituent...
|
|
WO/2003/102007A1 |
The invention provides a process for the synthesis of C-glycosides. In the process, an O-glycosyl trichloroimidate is reacted with a pyrrole in the presence of a Lewis acid and the C-glycoside isolated from the foregoing reaction mixture...
|
|
WO/2003/099836A1 |
An SGLT2 inhibiting compound is provided having the formula[Chemical structure] A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with ...
|
|
WO/2003/099870A2 |
The invention relates to a method for obtaining saturated or unsaturated oligo-mannuronates, characterized in that it consists in carrying out the following steps : a) brown algae are dispersed in an acidic medium in a heated state, havi...
|
|
WO/2003/099273A1 |
This invention relates to a new pharmaceutically useful compound which is a stoichiometrically 1:1 adduct of tramadol hydrochloride and topiramate, and to the manufacture and use thereof.
|
|
WO/2003/087093A1 |
A novel glucopyranoside, 6-hydroxy-2-p-hydroxybenzylbenzofuran-7-C-β-D-glucopyranosi
de of the formula (1) isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a phar...
|
|
WO/2003/082887A1 |
The present invention relates to a novel compound 8-(C-β-D-glucopyranosyl)-7,3', 4'- trihydroxyflavone, isolated from Pterocarpus marsupium useful in the treatment of diabetes. The present invention also relates to a method for the prep...
|
|
WO/2003/082886A1 |
The invention relates to methods for producing D-glucuronic acid. Said D-glucuronic acid (GA) and the derivatives thereof (lactone, salts, amides etc.) are represented in the form of highly active biological compounds which are largely u...
|
|
WO/2003/079980A2 |
Disclosed are caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins and analogs thereof to treat conditions and diseases such as bacterial infections.
|
|
WO/2003/080634A1 |
A novel glucopyranoside, 2, 6 - dihydroxy -2 - (P -hydroxybenzyl) - 3 (2H) benzofuran-7-c-β-D-glucopyranoside of the formula 1 isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention al...
|
|
WO/2003/073988A2 |
Disclosed are glycosides, orthoester glycosides and glycuronamides of fluoxetine and analogs thereof to treat conditions and diseases such as depression.
|
|
WO/2003/064439A2 |
The invention relates to the use of sialic carbohydrates of general formula (I), containing at least one carbohydrate unit of general formula (II) for the immune modulation, immune suppression and in the prevention and treatment of infec...
|
|
WO/2003/059866A1 |
Compounds represented by the general formulae (I-1), (I-2), (I-3) and (I-4) and having excellent antitumor activity: (I-1) (I-2) (I-3) (I-4) wherein R1, R2, R3, m, n and R4 are each as defined in the description.
|
